BeOne Medicines is an oncology company which involved in discovering and developing treatments to cancer patients. BeOne Medicines, formerly known as BeiGene Ltd., is based in SAN CARLOS, Calif.
| Revenue (Most Recent Fiscal Year) | $5.34B |
| Net Income (Most Recent Fiscal Year) | $286.93M |
| PE Ratio (Current Year Earnings Estimate) | 40.72 |
| PE Ratio (Trailing 12 Months) | 63.14 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.42 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 91.76 |
| Pre-Tax Margin (Trailing 12 Months) | 14.16% |
| Net Margin (Trailing 12 Months) | 10.70% |
| Return on Equity (Trailing 12 Months) | 14.23% |
| Return on Assets (Trailing 12 Months) | 7.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.40 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.06 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.17 |
| Inventory Turnover (Trailing 12 Months) | 1.07 |
| Book Value per Share (Most Recent Fiscal Quarter) | $47.13 |
| Earnings per Share (Most Recent Fiscal Quarter) | $2.05 |
| Earnings per Share (Most Recent Fiscal Year) | $2.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $5.68 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 109.79M |
| Free Float | 102.99M |
| Market Capitalization | $39.38B |
| Average Volume (Last 20 Days) | 0.40M |
| Beta (Past 60 Months) | 0.51 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.19% |
| Percentage Held By Institutions (Latest 13F Reports) | 48.55% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |